Berberine prevents nigrostriatal dopaminergic neuronal loss and suppresses hippocampal apoptosis in mice with Parkinson's disease

International Journal of Molecular Medicine

Volumn 33, Issue 4, 2014, Pages 870-878

  Kim, Mia ^a   Cho, K I H O ^a   Shin, Mal Soon ^b   Lee, Jae Min ^b   Cho, Han Sam ^b   Kim, Chang J U ^b   Shin, Dong Hoon ^c   Yang, Hyeon Jeong ^d  

^a College of Oriental Medicine   (South Korea)

^b Kyung Hee University Hospital   (South Korea)

^c Korea University   (South Korea)

^d CHA University   (South Korea)

Author keywords

Apoptosis; Berberine; Neurogenesis; Parkinson's disease; Tyrosine hydroxylase

Indexed keywords

1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; BERBERINE; CASPASE 3; PROTEIN BAX; PROTEIN BCL 2;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; CELL LOSS; CONTROLLED STUDY; COORDINATION; CORPUS STRIATUM; DENTATE GYRUS; DNA FRAGMENTATION; DOPAMINE DEPLETION; DOPAMINE METABOLISM; DOPAMINERGIC NERVE CELL; DRUG EFFECT; HIPPOCAMPUS; LOCOMOTION; MALE; MOUSE; NERVE CELL NECROSIS; NERVOUS SYSTEM DEVELOPMENT; NIGRONEOSTRIATAL SYSTEM; NONHUMAN; PARKINSON DISEASE; PRIORITY JOURNAL; PROTEIN EXPRESSION; SHORT TERM MEMORY; TREATMENT RESPONSE; WALKING;

ANIMALS; APOPTOSIS; BCL-2-ASSOCIATED X PROTEIN; BERBERINE; CASPASE 3; DENTATE GYRUS; DNA FRAGMENTATION; DOPAMINERGIC NEURONS; HIPPOCAMPUS; MALE; MEMORY, SHORT-TERM; MICE; MOTOR ACTIVITY; NEUROGENESIS; NEUROPROTECTIVE AGENTS; PARKINSON DISEASE; SUBSTANTIA NIGRA; TYROSINE 3-MONOOXYGENASE;

EID: 84899514521     PISSN: 11073756     EISSN: 1791244X     Source Type: Journal    
DOI: 10.3892/ijmm.2014.1656     Document Type: Article

References (42)

1. Dauer W and Przedborski S: Parkinson's disease: Mechanisms and models. Neuron 39: 889-909, 2003. (Pubitemid 37130207)
2. Park JH and Enikolopov G: Transient elevation of adult hippocampal neurogenesis after dopamine depletion. Exp Neurol 222: 267-276, 2010.
3. Asanuma M, Miyazaki I and Ogawa N: Dopamine- or L-DOPA-induced neurotoxicity: the role of dopamine quinone formation and tyrosinase in a model of Parkinson's disease. Neurotox Res 5: 165-176, 2003.
4. Sung YH, Kim SC, Hong HP, Park CY, Shin MS, Kim CJ, Seo JH, Kim DY, Kim DJ and Cho HJ: Treadmill exercise ameliorates dopaminergic neuronal loss through suppressing microglial activation in Parkinson's disease mice. Life Sci 91: 1309-1316, 2012.
5. Yoon MC, Shin MS, Kim TS, Kim BK, Ko IG, Sung YH, Kim SE, Lee HH, Kim YP and Kim CJ: Treadmill exercise suppresses nigrostriatal dopaminergic neuronal loss in 6-hydroxydopamine-induced Parkinson's rats. Neurosci Lett 423: 12-17, 2007.
6. Eriksson PS, Perfilieva E, Bjork-Eriksson T, Alborn AM, Nordborg C, Peterson DA and Gage FH: Neurogenesis in the adult human hippocampus. Nat Med 4: 1313-1317, 1998. (Pubitemid 28512114)
7. Kempermann G, Jessberger S, Steiner B and Kronenberg G: Milestones of neuronal development in the adult hippocampus. Trends Neurosci 27: 447-452, 2004. (Pubitemid 38951037)
8. Kim SE, Ko IG, Kim BK, Shin MS, Cho S, Kim CJ, Kim SH, Baek SS, Lee EK and Jee YS: Treadmill exercise prevents aging-induced failure of memory through an increase in neurogenesis and suppression of apoptosis in rat hippocampus. Exp Gerontol 45: 357-365, 2010.
9. Shin MS, Ko IG, Kim SE, Kim BK, Kim TS, Lee SH, Hwang DS, Kim CJ, Park JK and Lim BV: Treadmill exercise ameliorates symptoms of methimazole-induced hypothyroidism through enhancing neurogenesis and suppressing apoptosis in the hippocampus of rat pups. Int J Dev Neurosci 31: 214-223, 2013.
10. Dash PK, Mach, SA and Moore AN: Enhanced neurogenesis in the rodent hippocampus following traumatic brain injury. J Neurosci Res 63: 313-319, 2001. (Pubitemid 32115278)
11. Felling RJ and Levison SW: Enhanced neurogenesis following stroke. J Neurosci Res 73: 277-283, 2003. (Pubitemid 36918091)
12. Ma L, Cui XL, Wang Y, Li XW, Yang F, Wei D and Jiang W: Aspirin attenuates spontaneous recurrent seizures and inhibits hippocampal neuronal loss, mossy fiber sprouting and aberrant neurogenesis following pilocarpine-induced status epilepticus in rats. Brain Res 21: 103-113, 2012.
13. Hwang L, Choi IY, Kim SE, Ko IG, Shin MS, Kim CJ, Kim SH, Jin JJ, Chung JY and Yi JW: Dexmedetomidine ameliorates intracerebral hemorrhage-induced memory impairment by inhibiting apoptosis and enhancing brain-derived neurotrophic factor expression in the rat hippocampus. In J Mol Med 31: 1047-1056, 2013.
14. Savitz SI and Rosenbaum DM: Apoptosis in neurological disease. Neurosurgery 42: 555-574, 1998. (Pubitemid 28128742)
15. Cohen GM: Caspases: the executioners of apoptosis. Biochem J 326: 1-16, 1997.
16. Oltvai ZN, Milliman CL and Korsmeyer SJ: Bcl-2 heterodimerizes in vivo with a conserved homolog, Bax, that accelerates programmed cell death. Cell 74: 609-619, 1993. (Pubitemid 23259742)
17. Wolf BB, Schuler M, Echeverri F and Green DR: Caspase-3 is the primary activator of apoptotic DNA fragmentation via DNA fragmentation factor-45/inhibitor of caspase-activated DNase inactivation. J Biol Chem 274: 30651-30656, 1999.
18. Imanshahidi M and Hosseinzadeh H: Pharmacological and therapeutic effects of Berberis vulgaris and its active constituent, berberine. Phytother Res 22: 999-1012, 2008.
19. Kulkarni SK and Dhir A: On the mechanism of antidepressant-like action of berberine chloride. Eur J Pharmacol 589: 163-172, 2008.
20. Bhutada P, Mundhada Y, Bansod K, Tawari S, Patil S, Dixit P, Umathe S and Mundhada D: Protection of cholinergic and antioxidant system contributes to the effect of berberine ameliorating memory dysfunction in rat model of streptozotocin-induced diabetes. Behav Brain Res 220: 30-41, 2011.
21. Zhu F and Qian C: Berberine chloride can ameliorate the spatial memory impairment and increase the expression of interleuin-1beta and inducible nitric oxide synthase in the rat model of Alzheimer's disease. BMC Neurosci 7: 78, 2006.
22. Hung TM, Dang NH, Kim JC, Jang HS, Ryoo SW, Lee JH, Choi JS, Bae K and Min BS: Alkaloids from roots of Stephania rotunda and their cholinesterase inhibitory activity. Planta Med 76: 1762-1764, 2010.
23. Zhang Q, Qian Z, Pan L, Li H and Zhu H: Hypoxia-inducible factor 1 mediates the anti-apoptosis of berberine in neurons during hypoxia/ischemia. Acta Physiol Hung 99: 311-323, 2012.
24. Bae J, Lee D, Kim YK, Gil M, Lee JY and Lee KJ: Berberine protects 6-hydroxydopamine-induced human dopaminergic neuronal cell death through the induction of heme oxygenase-1. Mol Cells 35: 151-157, 2013.
25. Kwon IH, Choi HS, Shin KS, Lee BK, Lee CK, Hwang BY, Lim SC and Lee MK: Effects of berberine on 6-hydroxydopamine-induced neurotoxicity in PC12 cells and a rat model of Parkinson's disease. Neurosci Lett 486: 29-33, 2010.
26. Miyoshi E, Wietzikoski S, Camplessei M, Silveira R, Takahashi RN and Da Cunha C: Impaired learning in a spatial working memory version and in a cued version of the water maze in rats with MPTP-induced mesencephalic dopaminergic lesions. Brain Res Bull 58: 41-47, 2002. (Pubitemid 34732994)
27. Schneider JS, Tinker JP, VanVelson M and Giardiniere M: Effects of the partial glycine agonist D-cycloserine on cognitive functioning in chronic low dose MPTP-treated monkeys. Brain Res 860: 190-194, 2000. (Pubitemid 30155856)
28. Meredith GE, Totterdell S, Potashkin JA and Surmeier DJ: Modeling PD pathogenesis in mice: advantages of a chronic MPTP protocol. Parkinsonism Relat Disord 14 (Suppl 2): S112-S115, 2008.
29. Lau YS, Trobough KL, Crampton JM and Wilson JA: Effects of probenecid on striatal dopamine depletion in acute and long-term 1-methyl-4-phenyl-1,2,3,6- tetrahydropyridine (MPTP)-treated mice. Gen Pharmacol 21: 181-187, 1990. (Pubitemid 20097400)
30. Meng XH, Liu P, Wang H, Zhao XF, Xu ZM, Chen GH and Xu DX: Gender-specific impairments on cognitive and behavioral development in mice exposed to fenvalerate during puberty. Toxicol Lett 203: 245-251, 2011.
31. Nutt JG, Carter JH and Sexton GJ: The dopamine transporter: importance in Parkinson's disease. Ann Neurol 55: 766-773, 2004. (Pubitemid 38702571)
32. Von Bohlen and Halbach O: Modeling neurodegenerative diseases in vivo review. Neurodegener Dis 2: 313-320, 2005.
33. Schintu N, Frau L, Ibba M, Garau A, Carboni E and Carta AR: Progressive dopaminergic degeneration in the chronic MPTPp mouse model of Parkinson's disease. Neurotox Res 16: 127-139, 2009.
34. Emre M: Dementia associated with Parkinson's disease. Lancet Neurol 2: 229-237, 2003.
35. Ho YJ, Ho SC, Pawlak CR and Yeh KY: Effects of D-cycloserine on MPTP-induced behavioral and neurological changes: potential for treatment of Parkinson's disease dementia. Behav Brain Res 219: 280-290, 2011.
36. Peng J, Xie L, Jin K, Greenberg DA and Andersen JK: Fibroblast growth factor 2 enhances striatal and nigral neurogenesis in the acute 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine model of Parkinson's disease. Neuroscience 153: 664-570, 2008.
37. Kim SE, Ko IG, Park CY, Shin MS, Kim CJ and Jee YS: Treadmill and wheel exercise alleviate lipopolysaccharide-induced short-term memory impairment by enhancing neuronal maturation in rats. Mol Med Rep 7: 31-36, 2013.
38. Lesemann A, Reinel C, Hühnchen P, Pilhatsch M, Hellweg R, Klaissle P, Winter C and Steiner B: MPTP-induced hippocampal effects on serotonin, dopamine, neurotrophins, adult neurogenesis and depression-like behavior are partially influenced by fluoxetine in adult mice. Brain Res 1457: 51-69, 2012.
39. Parent JM: Injury-induced neurogenesis in the adult mammalian brain. Neuroscientist 9: 261-272, 2003.
40. Liedhegner EA, Steller KM and Mieyal JJ: Levodopa activates apoptosis signaling kinase 1 (ASK1) and promotes apoptosis in a neuronal model: implications for the treatment of Parkinson's disease. Chem Res Toxicol 24: 1644-1652, 2011.
41. Elmore S: Apoptosis: a review of programmed cell death. Toxicol Pathol 35: 495-516, 2007.
42. Zhou XQ, Zeng XN, Kong H and Sun XL: Neuroprotective effects of berberine on stroke models in vitro and in vivo. Neurosci Lett 447: 31-36, 2008.